HCM Q3 2022 Earnings — HUTCHMED (China) Limited Revenue & Financial Results | Market Cap Arena

HCMHUTCHMED (China) Limited

$3B

Q3 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$112M+12.9% YoY

Gross Profit

-$77M-68.9% margin

Operating Income

-$105M-94.0% margin

Net Income

-$99M-88.2% margin

EPS (Diluted)

$-0.60

QoQ Revenue Growth

-44.5%

Cash Flow

Operating Cash Flow

-$89M

Free Cash Flow

-$100M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$393M

Stockholders' Equity

$610M

Cash & Equivalents

$313M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$112M	$99M	+12.9%
Gross Profit	-$77M	-$56M	-37.7%
Operating Income	-$105M	-$92M	-14.3%
Net Income	-$99M	-$46M	-114.6%